Neurogene Receives FDA Approval to Proceed with Low-Dose Trial for Rett Syndrome Therapy

MT Newswires Live11-18

Neurogene (NGNE) said Monday that the US Food and Drug Administration has allowed the company to continue an early-stage trial using a lower dose of NGN-401, the company's intended gene therapy for Rett syndrome, a rare genetic neurological disorder.

The company said it had paused the higher-dose cohort of the study following a previously disclosed emerging treatment-related serious adverse event in a trial participant. It also said it does not plan to enroll any more participants at the higher-dose level.

So far, the company said it had not received reports of other treatment-related serious adverse events in the trial. However, it said that it no longer expects to complete enrollment of participants in the low-dose cohort in Q4.

Shares of the company fell more than 18% in premarket activity.

Price: 28.00, Change: -6.51, Percent Change: -18.88

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2484621495?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-18 20:39","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2484621495","market":"hk","top_or_hot":-1,"title":"Neurogene Receives FDA Approval to Proceed with Low-Dose Trial for Rett Syndrome Therapy","media":"MT Newswires Live","content":"<html><body><p> Neurogene (NGNE) said Monday that the US Food and Drug Administration has allowed the company to continue an early-stage trial using a lower dose of NGN-401, the company's intended gene therapy for Rett syndrome, a rare genetic neurological disorder.</p><p>The company said it had paused the higher-dose cohort of the study following a previously disclosed emerging treatment-related serious adverse event in a trial participant. It also said it does not plan to enroll any more participants at the higher-dose level.</p><p>So far, the company said it had not received reports of other treatment-related serious adverse events in the trial. However, it said that it no longer expects to complete enrollment of participants in the low-dose cohort in Q4.</p><p>Shares of the company fell more than 18% in premarket activity.</p><p>Price: 28.00, Change: -6.51, Percent Change: -18.88</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Neurogene Receives FDA Approval to Proceed with Low-Dose Trial for Rett Syndrome Therapy</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nNeurogene Receives FDA Approval to Proceed with Low-Dose Trial for Rett Syndrome Therapy\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-18 20:39 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.mtnewswires.com/><strong>MT Newswires Live</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Neurogene (NGNE) said Monday that the US Food and Drug Administration has allowed the company to continue an early-stage trial using a lower dose of NGN-401, the company's intended gene therapy for ...</p>\n\n<a href=\"https://www.mtnewswires.com/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"NGNE","symbol_name":"NEUROGENE INC","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2484621495","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2484621495","pubTimestamp":1731933564,"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Neurogene  said Monday that the US Food and Drug Administration has allowed the company to continue an early-stage trial using a lower dose of NGN-401, the company's intended gene therapy for Rett syndrome, a rare genetic neurological disorder.The company said it had paused the higher-dose cohort of the study following a previously disclosed emerging treatment-related serious adverse event in a trial participant. It also said it does not plan to enroll any more participants at the higher-dose level.So far, the company said it had not received reports of other treatment-related serious adverse events in the trial. However, it said that it no longer expects to complete enrollment of participants in the low-dose cohort in Q4.Shares of the company fell more than 18% in premarket activity.Price: 28.00, Change: -6.51, Percent Change: -18.88","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"NGNE":"NEUROGENE INC","BK4139":"生物科技"},"translate_title":"Neurogene获得FDA批准继续进行Rett综合征治疗低剂量试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NGNE":0.9},"content_text":"Neurogene (NGNE) said Monday that the US Food and Drug Administration has allowed the company to continue an early-stage trial using a lower dose of NGN-401, the company's intended gene therapy for Rett syndrome, a rare genetic neurological disorder.The company said it had paused the higher-dose cohort of the study following a previously disclosed emerging treatment-related serious adverse event in a trial participant. It also said it does not plan to enroll any more participants at the higher-dose level.So far, the company said it had not received reports of other treatment-related serious adverse events in the trial. However, it said that it no longer expects to complete enrollment of participants in the low-dose cohort in Q4.Shares of the company fell more than 18% in premarket activity.Price: 28.00, Change: -6.51, Percent Change: -18.88","kind":null,"is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2484621495"}